Asset Details
Do you wish to reserve the book?
Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplantation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplantation
Do you wish to request the book?
Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplantation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplantation
2006
Overview
Induction therapy reduces the frequency of acute rejection and delayed graft function. In this study in patients at high risk for acute rejection or delayed graft function who received a cadaveric renal transplant induction therapy with rabbit antithymocyte globulin reduced the incidence and severity of acute rejection, but not the incidence of delayed graft function, as compared with a monoclonal interleukin-2 receptor antibody. Patient and graft survival were similar in the two groups.
In patients at high risk for acute rejection or delayed graft function who received a cadaveric renal transplant, induction therapy with rabbit antithymocyte globulin reduced the incidence and severity of acute rejection, but not the incidence of delayed graft function, as compared with basiliximab.
Two events occurring early in the post-transplantation period, acute rejection and delayed graft function, negatively affect graft survival.
1
–
3
Patients with delayed graft function have an increased risk of acute rejection, and graft survival is superior in patients who do not have delayed graft function or acute rejection as compared with those who have either or both.
4
–
7
The up-regulation of immunogenic molecules during brain death and during the subsequent procurement of organs predisposes allografts from deceased donors to acute rejection and delayed function. Induction therapy is specific therapy given at the time of transplantation to lower the incidence of . . .
Publisher
Massachusetts Medical Society
Subject
/ Animals
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Antilymphocyte Serum - adverse effects
/ Antilymphocyte Serum - therapeutic use
/ Biological and medical sciences
/ Cadaver
/ Delayed Graft Function - prevention & control
/ Female
/ Graft Rejection - prevention & control
/ Humans
/ Immunosuppressive Agents - adverse effects
/ Immunosuppressive Agents - therapeutic use
/ Kidney Transplantation - mortality
/ Male
/ Rabbits
/ Receptors, Interleukin-2 - antagonists & inhibitors
/ Recombinant Fusion Proteins - adverse effects
/ Recombinant Fusion Proteins - therapeutic use
/ Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
